Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Esophagogastric Junction Adenocarcinoma After Radical Gastrectomy

NCT05180734 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT05180734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05180734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Esophagogastric Junction Adenocarcinoma After Radical Gastrectomy
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 10, 2022
Completion date
July 31, 2028
Enrollment
878 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

gastric or esophagogastric junction adenocarcinoma